Similar articles

• Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.

  Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, O'Neil K, Sandhaus R, Crystal RG. Stoller JK, et al. Chest. 2003 May;123(5):1425-34. doi: 10.1378/chest.123.5.1425. Chest. 2003. PMID: 12740257
• Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group.

  McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, Crystal RD. McElvaney NG, et al. Chest. 1997 Feb;111(2):394-403. doi: 10.1378/chest.111.2.394. Chest. 1997. PMID: 9041988
• Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society.

  [No authors listed] [No authors listed] CMAJ. 1992 Mar 15;146(6):841-4. CMAJ. 1992. PMID: 1544074 Free PMC article. Review. No abstract available.
• American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

  American Thoracic Society; European Respiratory Society. American Thoracic Society, et al. Am J Respir Crit Care Med. 2003 Oct 1;168(7):818-900. doi: 10.1164/rccm.168.7.818. Am J Respir Crit Care Med. 2003. PMID: 14522813 No abstract available.
• Alpha-1 antitrypsin augmentation therapy.

  Wewers MD, Crystal RG. Wewers MD, et al. COPD. 2013 Mar;10 Suppl 1:64-7. doi: 10.3109/15412555.2013.764402. COPD. 2013. PMID: 23527997 Review.